NDA 018058 · Curium
Gallium Citrate Ga 67
Gallium Citrate Ga-67 · Injection
Last checked: Nov 20, 2026Latest source record: Mar 19, 2014 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1979
Feb 1, 1979
Approved uses
1
Original approval plus efficacy supplements
Registered trials
2
1 Phase 3, 0 recruiting
FAERS reports
4
4 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 13, 2025.
INDICATIONS AND USAGE Gallium Citrate Ga 67 Injection may be useful to demonstrate the presence and extent of Hodgkin's disease, lymphoma, and bronchogenic carcinoma. Positive gallium Ga-67 uptake in the absence of prior symptoms warrants follow-up as an indication of a potential disease state. Gallium Citrate Ga 67 Injection may be useful as an aid in detecting some acute inflammatory lesions.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 1, 1979 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
- GALLIUM CITRATE GA 67 · GALLIUM CITRATE GA-67 2mCi/ML · INJECTABLE, INJECTION · Prescription · TE BS
Clinical trials
Interventional ClinicalTrials.gov studies with "Gallium Ga-67" as an intervention, any sponsor and status, largest first.
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT00477503 · 1 participants · Start May 2007 · Primary completion Jul 2009
Drug: Gallium-67 Citrate (Ga-67); In-111 DTPA (In-111 pentetate) · For: Central Nervous System Tumors; Brain Tumors
Sites: Houston, Texas
- 68Ga Citrate PET/MRI for Evaluation of Fever of Unknown Origin (FUO)Pivotal-lookingWithdrawn
Carina Mari ApariciAcademic, hospital or other
NCT04139395 · 0 participants · Start Jan 15, 2019 · Primary completion Dec 20, 2020
Drug: 68Ga-Citrate PET/MRI; 67Ga-Citrate SPECT · For: Fever of Unknown Origin
Sites: Palo Alto, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- erythema2
- inflammation2
- rash pruritic2
- urticaria2
- anaphylactic reaction1
- blood pressure decreased1
- cardiac arrest1
- device related thrombosis1
- electrocardiogram abnormal1
- lung opacity1
- off label use1
- palpable purpura1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Curium
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.